InvestorsHub Logo
Followers 0
Posts 350
Boards Moderated 0
Alias Born 05/08/2015

Re: Wilson-castaway post# 20302

Wednesday, 08/17/2016 3:50:48 PM

Wednesday, August 17, 2016 3:50:48 PM

Post# of 73676
I currently don't own shares, but I listened to it.

My thoughts... he tried to address the dilution issue and did a good job explaining how they aren't guilty of any wrongdoing and how most people don't understand funding and the cost of this type of venture, but he didn't actually comment around the current price action or any timeframe. I personally do not like leaders of organizations coming out and saying where they think their stock price will be or mentioning that he got a call from "one of the worlds largest" or something to that affect pharma companies. It's misleading and it creates a very black/white environment of success. AMDA did the same thing in relation to an FDA approval whereby the FDA approval became the only important factor and they've lost 75% due to a delay while other positive news occurred. I think its good to keep people informed, but assuring investors that you're working diligently and giving regular updates is WAY better than saying "in the next few weeks THIS will happen" because if it ends up taking two months you've failed.

I like his acknowledgement of cash burn and his explanation of funds usage, i disagree with his confidence in getting a pain med to market by Q1 of 2017, i think he's being way too optimistic. That's a biggie for funding purposes and i'd be interested to see their estimates on revenue. Unless you're a true true 5-10+ year long, patents are just good for pops, but its good to see the stream. Seems like he's working, but they have a long long long way to go.

Overall just middle of the road for me. I was actually expecting something over the top thinking that the delay in the quarterly may be intentional, but doesn't seem to be the case.